Canaccord Genuity Raises Price Target on Auxilium Pharmaceuticals (AUXL); Testim Tests Well

Canaccord Genuity maintains a 'Buy' on Auxilium Pharmaceuticals (NASDAQ: AUXL) price target raised to $33.00 (from $27.00)

Analyst, Salveen Richter, said, "Post reporting a Q2 top- and bottom-line beat and commitment to sustained profitability for FY12+, AUXL detailed its focus to accelerate both the Xiaflex and Testim revenue trajectories...we raise our Testim revenue estimates for FY12+ (peak revenue $292.4M from $255.9M), partially offset by a decrease in Xiaflex revenue in Dupuytren's (peak revenue $84.2M from $100.4M, due to current trends)."

"We see the next key catalysts as Q4 P1b top-line data in cellulite, Q1/13 P2a top-line data in FSS, and a likely mid-13 FDA panel in Peyronie’s (data at SMSNA, Aug 26-30)."

For an analyst ratings summary and ratings history on Auxilium Pharmaceuticals click here. For more ratings news on Auxilium Pharmaceuticals click here.

Shares of Auxilium Pharmaceuticals closed at $26.94 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• Indigo Paints (INDIGOPN:IN) PT Raised to INR1,300 at ICICI Securities